—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Travere Therapeutics Inc (TVTX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for TVTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where TVTX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 1.14 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How TVTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.14 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Travere Therapeutics Inc moved 1.14% on average · correlation 0.16 · higher than 91% of US names
  • Beta, last 3 months 0.80 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.82% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.32% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against TVTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Travere Therapeutics Inc

TVTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Travere Therapeutics develops and sells medicines for rare kidney and metabolic disorders. Its lead product, Filspari, treats IgA nephropathy by targeting two pathways involved in the disease's progression, and Thiola treats cystinuria, a genetic disorder causing kidney stones. It also runs early-stage programmes for related kidney and enzyme conditions. The company is based in San Diego and was previously named Retrophin.
Where it sits in the stack
Travere sits outside our AI build-out stack; it belongs to the healthcare and biotechnology sleeve of our universe rather than any Closelooknet index layer.
Who it is priced against
No peer group is assigned to Travere in our coverage; the market sometimes compares it with other rare-disease specialists such as Alnylam Pharmaceuticals.
Why Closelooknet tracks it
Travere holds no Closelooknet index seat and carries no Closelooknet score; the diary noted it once, in a Midday 10 quoting Barchart's large-cap new-high list where it appeared among the health-care and biotech names.
What the diary watches
Whether Filspari's use in kidney disease keeps widening and whether the clinical-stage programmes for other rare conditions progress toward approval.

Travere Therapeutics Inc (TVTX) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Guggenheim, 2026-09-24

The Street on this name

Analyst actions and the latest print for TVTX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Guggenheim — target 89 Target set to $89 (+48.8% to spot) 2026-09-24

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What TVTX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +13.1% in FY2025 45 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Travere Therapeutics Inc (TVTX)?

Travere Therapeutics Inc trades as TVTX on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is TVTX in a Closelooknet index?

Not currently — Travere Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does TVTX trade against its moving averages?

Pullback inside an uptrend stack: Trades -4.1% vs the 50-day and +33.9% vs the 200-day average, 13.5% below the 52-week high and +169.5% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Travere Therapeutics Inc trade when bond yields rise?

Over the past year Travere Therapeutics Inc had a beta of 1.14 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 91% of US names. On the 10 sessions in which long bonds fell most it moved −0.82% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Travere Therapeutics Inc?

Travere Therapeutics Inc appears in 1 Closelooknet piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Travere Therapeutics Inc do?

Travere Therapeutics develops and sells medicines for rare kidney and metabolic disorders. Its lead product, Filspari, treats IgA nephropathy by targeting two pathways involved in the disease's progression, and Thiola treats cystinuria, a genetic disorder causing kidney stones. It also runs early-stage programmes for related kidney and enzyme conditions. No peer group is assigned to Travere in our coverage; the market sometimes compares it with other rare-disease specialists such as Alnylam Pharmaceuticals.

Where does Travere Therapeutics Inc sit in the AI build-out?

Travere sits outside our AI build-out stack; it belongs to the healthcare and biotechnology sleeve of our universe rather than any Closelooknet index layer. Travere holds no Closelooknet index seat and carries no Closelooknet score; the diary noted it once, in a Midday 10 quoting Barchart's large-cap new-high list where it appeared among the health-care and biotech names.

Does Travere Therapeutics Inc pay a dividend?

No cash distribution shows in Travere Therapeutics Inc’s price series over the last three years. The share count rose 13.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Travere Therapeutics Inc recently?

The most recent analyst action on Travere Therapeutics Inc on the Closelooknet wire is a price target by Guggenheim on 2026-09-24 (target 89). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for TVTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.